BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31791583)

  • 1. MBNL1 regulates resistance of HeLa cells to cisplatin via Nrf2.
    Wang T; Liu Q; Duan L
    Biochem Biophys Res Commun; 2020 Feb; 522(3):763-769. PubMed ID: 31791583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
    Su J; Zhang F; Li X; Liu Z
    Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin resistance in human cervical cancer cells.
    Xia J; Yu X; Song X; Li G; Mao X; Zhang Y
    Mol Med Rep; 2017 Jan; 15(1):488-494. PubMed ID: 27959427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor- kappa B (NF-κB) pathway.
    Aktepe OH; Şahin TK; Güner G; Arik Z; Yalçin Ş
    Turk J Med Sci; 2021 Feb; 51(1):368-374. PubMed ID: 32718121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2.
    Yin Y; Liu H; Xu J; Shi D; Zhai L; Liu B; Wang L; Liu G; Qin J
    Oncol Rep; 2018 Dec; 40(6):3479-3488. PubMed ID: 30542710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancer of mRNA Decapping protein 4 (EDC4) interacts with replication protein a (RPA) and contributes to Cisplatin resistance in cervical Cancer by alleviating DNA damage.
    Wu X; Zhong Y; Chen Q; Zhang X; Zhang H
    Hereditas; 2020 Oct; 157(1):41. PubMed ID: 33054858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
    Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
    Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer.
    Fang X; Zhong G; Wang Y; Lin Z; Lin R; Yao T
    Cell Death Dis; 2020 Jul; 11(7):531. PubMed ID: 32661236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C β inhibits autophagy and sensitizes cervical cancer Hela cells to cisplatin.
    Li N; Zhang W
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28246354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Long Noncoding RNA Urothelial Cancer Associated 1 Promotes Cisplatin Resistance in Cervical Cancer.
    Wang B; Huang Z; Gao R; Zeng Z; Yang W; Sun Y; Wei W; Wu Z; Yu L; Li Q; Zhang S; Li F; Liu G; Liu B; Leng L; Zhan W; Yu Y; Yang G; Zhou S
    Cancer Biother Radiopharm; 2017 Apr; 32(3):101-110. PubMed ID: 28414550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.
    Wen Q; Liu Y; Lyu H; Xu X; Wu Q; Liu N; Yin Q; Li J; Sheng X
    Int J Gynecol Cancer; 2017 Jul; 27(6):1096-1108. PubMed ID: 28472815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer.
    Zhang WY; Liu YJ; He Y; Chen P
    J Cell Physiol; 2019 Apr; 234(4):4302-4313. PubMed ID: 30221354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression.
    Wu J; Zhang L; Li H; Wu S; Liu Z
    Biochem Biophys Res Commun; 2019 Oct; 518(4):698-705. PubMed ID: 31472965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of organic cation transporter 3 to cisplatin cytotoxicity in human cervical cancer cells.
    Li Q; Peng X; Yang H; Rodriguez JA; Shu Y
    J Pharm Sci; 2012 Jan; 101(1):394-404. PubMed ID: 21905038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines.
    Chen X; Xiong D; Ye L; Yang H; Mei S; Wu J; Chen S; Mi R
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):603-613. PubMed ID: 30627777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells.
    Tao T; Yang X; Qin Q; Shi W; Wang Q; Yang Y; He J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
    Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pin1 modulates chemo-resistance by up-regulating FoxM1 and the involvements of Wnt/β-catenin signaling pathway in cervical cancer.
    Wang T; Liu Z; Shi F; Wang J
    Mol Cell Biochem; 2016 Feb; 413(1-2):179-87. PubMed ID: 26820938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of NRF2 cascade in determining the differential response of cervical cancer cells to anticancer drugs: an in vitro study.
    Ramesh PS; Raja S; Udayakumar SH; Chandrashekar S; Nataraj SM; Devegowda D
    Mol Biol Rep; 2022 Jan; 49(1):109-119. PubMed ID: 34674139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-144 reverses cisplatin resistance in cervical cancer via targeting LHX2.
    Shi F; Su J; Liu Z; Wang J; Wang T
    J Cell Biochem; 2019 Sep; 120(9):15018-15026. PubMed ID: 31017720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.